Related Experiment Video
Updated: Jul 15, 2026
04:03
Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery
Published on: March 28, 2025
Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid
H Hayashi1, T Higuchi, H Ichimiya
1Third Department of Medicine, Nagoya University School of Medicine, Japan.
Gastroenterology
|August 1, 1990
Summary
Ursodeoxycholic acid (UDCA) treatment improved liver function in primary sclerosing cholangitis by normalizing biliary enzymes and enhancing copper metabolism. However, UDCA did not reverse the underlying liver or bile duct scarring.
Area of Science:
- Hepatology
- Gastroenterology
- Pharmacology
Background:
- Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by bile duct inflammation and fibrosis.
- Asymptomatic PSC requires management strategies to prevent disease progression and complications.
- Ursodeoxycholic acid (UDCA) is a bile acid with potential therapeutic benefits in cholestatic liver diseases.
Observation:
- A single patient with asymptomatic primary sclerosing cholangitis received ursodeoxycholic acid (600 mg/day).
- Serum levels of biliary enzymes normalized within one month and remained stable for 26 months.
- Hepatic copper metabolism showed improvement, assessed via x-ray probe analysis, with UDCA replacing chenodeoxycholic acid.
Findings:
- Ursodeoxycholic acid treatment led to normalization of serum biliary enzymes in an asymptomatic PSC patient.
- UDCA administration improved hepatic copper metabolism during the treatment period.
- No significant changes were observed in biliary tract sclerosis or portal tract pathology.
Implications:
- Ursodeoxycholic acid may offer hepatoprotective effects in primary sclerosing cholangitis.
- The mechanism of protection appears linked to improved bile acid and copper metabolism.
- Further research is warranted to evaluate UDCA's efficacy in halting PSC progression.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:20Cholecystitis
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
01:25Chronic Pancreatitis I: Introduction
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...